|
|
||||||||
From Channing Lab (Drs. Kang and Grodstein), Department of Medicine, Brigham and Womens Hospital, Harvard Medical School; and the Department of Epidemiology (Dr. Grodstein), Harvard School of Public Health, Boston, MA.
Address correspondence and reprint requests to Dr. Jae Hee Kang, Channing Lab, 181 Longwood Ave., Boston, MA 02115; e-mail: nhjhk{at}channing.harvard.edu
Objective: To examine the relationship of nonsteroidal anti-inflammatory drug (NSAID) use and cognitive decline in young-old women.
Methods: The authors prospectively studied 16,128 Nurses Health Study participants, aged 70 to 81 years at baseline, who provided information on NSAID use and potential confounders in biennial questionnaires from 1976 through 1998. From 1995 through 2001, we administered, by telephone, six tests of cognitive function, including the Telephone Interview of Cognitive Status (TICS). Second interviews were begun 2 years later and completed on 13,255 women to date. The authors used multiple logistic regression to estimate relative risks (RR) of low baseline scores (defined as the bottom 10%) and substantial decline (worst 10%).
Results: Compared to never users, the RR was 0.75 (95% CI 0.59, 0.96) for a low baseline TICS score with current aspirin use of 15+ years duration, and 0.79 (95% CI 0.62, 1.02) for current use of NSAID (primarily ibuprofen) lasting 8+ years. Results for aspirin users were weaker on other tests, but long-term ibuprofen users had a RR of 0.75 (95% CI 0.56, 1.00) for a low baseline global score (combination of all six tests). The RR for substantial global cognitive decline was 0.93 (95% CI 0.68, 1.26) with long-term aspirin use, and 0.77 (95% CI 0.57, 1.05) with long-term ibuprofen use.
Conclusions: In these young-old women, current, long-term NSAID users, especially of nonaspirin agents, showed reduced odds of low cognitive function and possibly lower rates of substantial cognitive decline over 2 years. Continued follow-up will help determine if associations differ at older ages.
This article has been cited by other articles:
![]() |
Z. Arvanitakis, F. Grodstein, J. L. Bienias, J. A. Schneider, R. S. Wilson, J. F. Kelly, D. A. Evans, and D. A. Bennett Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology Neurology, June 3, 2008; 70(23): 2219 - 2225. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. DeLegge and A. Smoke Neurodegeneration and Inflammation Nutr Clin Pract, February 1, 2008; 23(1): 35 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Grodstein, J. H. Kang, R. J. Glynn, N. R. Cook, and J. M. Gaziano A Randomized Trial of Beta Carotene Supplementation and Cognitive Function in Men: The Physicians' Health Study II Arch Intern Med, November 12, 2007; 167(20): 2184 - 2190. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Kang, N. Cook, J. Manson, J. E Buring, and F. Grodstein Low dose aspirin and cognitive function in the women's health study cognitive cohort BMJ, May 12, 2007; 334(7601): 987 - 987. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kalaydjian, P. P. Zandi, K. L. Swartz, W. W. Eaton, and C. Lyketsos How migraines impact cognitive function: Findings from the Baltimore ECA Neurology, April 24, 2007; 68(17): 1417 - 1424. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. M. de Craen, J. Gussekloo, B. Vrijsen, and R. G. J. Westendorp Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia Am. J. Epidemiol., January 15, 2005; 161(2): 114 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Logroscino, J. H. Kang, and F. Grodstein Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years BMJ, March 6, 2004; 328(7439): 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
Minerva BMJ, June 5, 2003; 326(7401): 1274 - 1274. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |